Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
To investigate the effect of repeat oral dosing of CNV2197944 75 mg tid on the pain
experienced in post-herpetic neuralgia (PHN) as measured by changes in PI-NRS after three
weeks of treatment compared to the baseline period.